Literature DB >> 3042837

Analysis of bronchoalveolar lavage in allergic bronchopulmonary aspergillosis: divergent responses of antigen-specific antibodies and total IgE.

P A Greenberger1, L J Smith, C C Hsu, M Roberts, J L Liotta.   

Abstract

Bronchoalveolar lavage (BAL) was performed in eight patients with allergic bronchopulmonary aspergillosis (ABPA) at a time when chest roentgeongraphy did not reveal an infiltrate, and respiratory status was stable. BAL was tolerated well by all patients with only one patient experiencing mild wheezing. BAL fluid recovery averaged 40%, and total cells/lavage were 22.3 x 10(6) (range 3.5 to 49.5 x 10(6)). Cell viability, as determined by trypan blue exclusion, averaged 48% (range 34% to 60%). Mean values for cellular elements were macrophages, 62%; epithelial cells, 12%; lymphocytes, 16%; neutrophils (PMN), 4%; and eosinophils, 6%. Isotypic antibodies to Aspergillus fumigatus (Af) in BAL and serum were detected by an amplified indirect ELISA. Antibodies to Af in BAL expressed as optical density/albumin (milligrams per milliliter) were compared to BAL from six nonatopic patients. IgE-Af and IgA-Af in BAL were elevated in patients with ABPA compared with six nonatopic patients. The ratios of Ig-Af in BAL to peripheral blood in patients with ABPA were 48 (range 18 to 75) for IgE-Af, 96 (range 37 to 159) for IgA-Af, and 0.94 (range 0.24 to 1.40) for IgG-Af, suggesting local production of IgE-Af and IgA-Af in the bronchoalveolar compartment. Total serum IgE correlated directly with IgE-Af in BAL (rs = 0.67; p less than 0.02). However, the ratio of total BAL IgE/albumin divided by total serum IgE/albumin was 0.93 +/- 0.94, suggesting that the bronchoalveolar compartment is not the source of the significant elevations in total serum IgE in ABPA.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3042837     DOI: 10.1016/0091-6749(88)90995-5

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  10 in total

Review 1.  Eosinophils in innate immunity: an evolving story.

Authors:  Revital Shamri; Jason J Xenakis; Lisa A Spencer
Journal:  Cell Tissue Res       Date:  2010-11-03       Impact factor: 5.249

Review 2.  Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.

Authors:  A P Knutsen; R G Slavin
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 3.  Allergic bronchopulmonary aspergillosis.

Authors:  Richard B Moss
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

4.  Rise in total IgE as an indicator of allergic bronchopulmonary aspergillosis in cystic fibrosis.

Authors:  J L Marchant; J O Warner; A Bush
Journal:  Thorax       Date:  1994-10       Impact factor: 9.139

5.  Coexistence of allergic bronchopulmonary aspergillosis and allergic aspergillus sinusitis in a patient without clinical asthma.

Authors:  Gopal Ghosh; Brijesh Sharma; Ajay Chauhan; M P S Chawla
Journal:  BMJ Case Rep       Date:  2013-05-02

Review 6.  Allergic bronchopulmonary aspergillosis: a review.

Authors:  A Wardlaw; D M Geddes
Journal:  J R Soc Med       Date:  1992-12       Impact factor: 18.000

7.  A Case of Allergic Bronchopulmonary Aspergillosis (ABPA) in a Patient with a History of Cocaine Use and Tuberculosis.

Authors:  Noura Ayoubi; Samuel Jalali; Nikesh Kapadia
Journal:  Case Rep Med       Date:  2019-11-23

Review 8.  Azoles for allergic bronchopulmonary aspergillosis associated with asthma.

Authors:  P A B Wark; P G Gibson; A J Wilson
Journal:  Cochrane Database Syst Rev       Date:  2004

9.  The impact of Aspergillus fumigatus viability and sensitization to its allergens on the murine allergic asthma phenotype.

Authors:  Sumali Pandey; Scott A Hoselton; Jane M Schuh
Journal:  Biomed Res Int       Date:  2013-08-26       Impact factor: 3.411

10.  Allergic bronchopulmonary aspergillosis coupled with broncholithiasis in a non-asthmatic patient.

Authors:  Won-Jung Koh; Joungho Han; Tae Sung Kim; Kyung Soo Lee; Hye Won Jang; O Jung Kwon
Journal:  J Korean Med Sci       Date:  2007-04       Impact factor: 2.153

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.